Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment

AT Ruffin, H Li, L Vujanovic, DP Zandberg… - Nature Reviews …, 2023 - nature.com
Targeted immunotherapy has improved patient survival in head and neck squamous cell
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …

Oropharyngeal carcinoma with a special focus on HPV-related squamous cell carcinoma

RL Ferris, W Westra - Annual Review of Pathology: Mechanisms …, 2023 - annualreviews.org
Human papillomavirus–positive oropharyngeal squamous cell carcinoma (HPV-OPSCC)
has one of the most rapidly increasing incidences of any cancer in high-income countries …

[HTML][HTML] Role of E2F transcription factor in oral cancer: Recent insight and advancements

A Kassab, I Gupta, AE Al Moustafa - Seminars in cancer biology, 2023 - Elsevier
The family of mammalian E2F transcription factors (E2Fs) comprise of 8 members (E2F1-
E2F8) classified as activators (E2F1-E2F3) and repressors (E2F4-E2F8) primarily regulating …

[HTML][HTML] The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy

MPS Damasio, CS Nascimento, LM Andrade… - Frontiers in …, 2022 - frontiersin.org
Head and neck squamous cell carcinoma (HNSCC) encompass a group of complex entities
of tumours affecting the aerodigestive upper tract. The main risk factors are strongly related …

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of …

JP Machiels, Y Tao, L Licitra, B Burtness… - The Lancet …, 2024 - thelancet.com
Background Despite multimodal therapy, 5-year overall survival for locally advanced head
and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of …

HPV+ head and neck cancer–derived small extracellular vesicles communicate with TRPV1+ neurons to mediate cancer pain

KE Inyang, CM Evans, M Heussner, M Petroff… - Pain, 2024 - journals.lww.com
Severe pain is often experienced by patients with head and neck cancer and is associated
with a poor prognosis. Despite its frequency and severity, current treatments fail to …

[HTML][HTML] High risk-human papillomavirus in HNSCC: Present and future challenges for epigenetic therapies

L Ghiani, S Chiocca - International Journal of Molecular Sciences, 2022 - mdpi.com
Head and Neck Squamous Cell Carcinoma (HNSCC) is a highly heterogeneous group of
tumors characterized by an incidence of 650,000 new cases and 350,000 deaths per year …

[HTML][HTML] DNA damage response mechanisms in head and neck cancer: significant implications for therapy and survival

C Papalouka, M Adamaki, P Batsaki… - International Journal of …, 2023 - mdpi.com
Head and neck cancer (HNC) is a term collectively used to describe a heterogeneous group
of tumors that arise in the oral cavity, larynx, nasopharynx, oropharynx, and hypopharynx …

[HTML][HTML] Implications of oral dysbiosis and HPV infection in head and neck cancer: from molecular and cellular mechanisms to early diagnosis and therapy

M Constantin, MC Chifiriuc, G Mihaescu… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Head and neck cancer (HNC) is the sixth most common type of cancer, with more than half a
million new cases annually. This review focuses on the role of oral dysbiosis and HPV …

[HTML][HTML] HPV upregulates MARCHF8 ubiquitin ligase and inhibits apoptosis by degrading the death receptors in head and neck cancer

MI Khalil, C Yang, L Vu, S Chadha, H Nabors… - PLoS …, 2023 - journals.plos.org
The membrane-associated RING-CH-type finger ubiquitin ligase MARCHF8 is a human
homolog of the viral ubiquitin ligases Kaposi's sarcoma herpesvirus K3 and K5 that promote …